This study did not test afamelanotide in isolation. It asked whether adding an implant to narrowband UV-B phototherapy changed repigmentation outcomes. Primary publication record
Study snapshot
The randomized multicenter report analyzed 55 participants with nonsegmental vitiligo. Combination treatment produced greater repigmentation than phototherapy alone on reported measures. Results were not uniformly significant across every dimension of the scoring systems. The enrolled skin phototypes and extent of disease defined a selected study population. Primary publication
Our appraisal: preserve both the comparator and the scale
The appropriate treatment claim concerns the added intervention in the presence of phototherapy. It cannot establish the same effect without phototherapy, with a different formulation, or with an unverified product sold under a related peptide name.
Measurement choice matters as well. Two scoring systems can emphasize different aspects of a condition. A difference detected on one dimension does not require every other dimension to move, and it should not be used to erase an unfavorable or inconclusive result elsewhere.
Readers should distinguish the onset of repigmentation, its extent during treatment, and its durability afterward. These are separate outcomes. Improvement at one observation point is not proof of permanent disease reversal.
Subgroup observations require particular caution when the overall study is small. Apparent differences by skin type or body region can be useful for generating questions, but they need uncertainty estimates and an appropriate interaction analysis before becoming reliable comparative claims. Full review must also retain adverse events and the actual observation period. This page is an evidence appraisal, not instructions for tanning or self-treatment.
Frequently asked questions
Was afamelanotide tested alone?
No. The experimental arm combined it with phototherapy.
What was the main comparator?
Narrowband UV-B phototherapy without the implant.
Did every scoring dimension show the same result?
No. The report describes differences across measures.
Can an implant result validate any similarly named product?
No. Formulation and identity must be established separately.
Does repigmentation during treatment prove permanence?
No. Durability needs follow-up evidence.
Are small subgroup patterns definitive?
No. They require careful uncertainty and interaction assessment.
What is the central boundary?
This is an add-on trial in a defined clinical population, not a general tanning claim.